Amgen Inc. (AMGN) News

Amgen Inc. is successfully navigating a period of legacy patent expirations by accelerating its next-generation clinical pipeline and integrating artificial intelligence across its commercial and research platforms. Robert Bradway stated that the company remains on track to deliver attractive performance while positioning the business for sustained long-term growth. To support this trajectory, the company is accelerating late-stage pipeline programs and embedding artificial intelligence to drive enterprise efficiency.

Amgen has reinforced its dominance in the thyroid eye disease market following positive Phase 3 results for a subcutaneous formulation of TEPEZZA. Delivering efficacy on par with its intravenous predecessor, this development secures a multi-billion-dollar franchise while effectively neutralizing emerging competitive threats.